- Home
- QLGN vs BENF Comparison
QLGN vs BENF Comparison
Compare QLGN & BENF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- BENF
- Stock Information
- Founded
- QLGN 1996
- BENF 2003
- Country
- QLGN United States
- BENF United States
- Employees
- QLGN N/A
- BENF N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- BENF Blank Checks
- Sector
- QLGN Health Care
- BENF Finance
- Exchange
- QLGN Nasdaq
- BENF Nasdaq
- Market Cap
- QLGN 3.1M
- BENF 2.6M
- IPO Year
- QLGN N/A
- BENF N/A
- Fundamental
- Price
- QLGN $1.70
- BENF $0.44
- Analyst Decision
- QLGN
- BENF
- Analyst Count
- QLGN 0
- BENF 0
- Target Price
- QLGN N/A
- BENF N/A
- AVG Volume (30 Days)
- QLGN 43.3K
- BENF 7.2M
- Earning Date
- QLGN 08-14-2025
- BENF 09-19-2025
- Dividend Yield
- QLGN N/A
- BENF N/A
- EPS Growth
- QLGN N/A
- BENF N/A
- EPS
- QLGN N/A
- BENF N/A
- Revenue
- QLGN N/A
- BENF N/A
- Revenue This Year
- QLGN N/A
- BENF N/A
- Revenue Next Year
- QLGN N/A
- BENF $53.55
- P/E Ratio
- QLGN N/A
- BENF N/A
- Revenue Growth
- QLGN N/A
- BENF N/A
- 52 Week Low
- QLGN $1.61
- BENF $0.22
- 52 Week High
- QLGN $10.45
- BENF $3.33
- Technical
- Relative Strength Index (RSI)
- QLGN 30.88
- BENF 67.72
- Support Level
- QLGN $1.66
- BENF $0.36
- Resistance Level
- QLGN $1.77
- BENF $0.42
- Average True Range (ATR)
- QLGN 0.08
- BENF 0.06
- MACD
- QLGN 0.04
- BENF 0.01
- Stochastic Oscillator
- QLGN 12.77
- BENF 52.06
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About BENF Beneficient
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and an innovative financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.